Fermer le menu


Member of Lyonbiopole


Founded in January 2019, Vidium introduces a groundbreaking technology that enables the control and mastery of cellular genetic expression, accelerating and de-risking the development of innovative treatments, with already proven results in challenging health issues like cancer resistance. We revolutionize drug discovery by shifting the focus from a single molecular target to the underlying causal gene regulatory network of the cell.

We are a target discovery platform combining retro-engineering and AI applied to omics data to model and validate the key genetic relationships underlying random cell behavior, providing target ID and validation, biomarkers and mechanism of action of novel drugs.


Strategic application domain: Human Medicine

Application market: Genetic Disorders, Oncology, Others

Type of activity: Diagnostics, Therapeutics, Pharma or Biotech

Technologies: AI, NGS & Omics technologies, Others

Created on jan. 14th, 2019 - 10 employees



46 Allée d'Italie 69007 Lyon



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.